Page 20 - Codexis Inc News Today

Cathie Wood, founder and chief executive officer of ARK Investment Management, joined Bloomberg on June 9 and defended her ARK Innovation ETF, which has been notably battered from its peak in the COVID...

The Business Research Company’s Specialty Enzymes Global Market Report 2022: Market Size, Trends, And Forecast To 2026

Codexis (NASDAQ:CDXS – Get Rating) and Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Profitability This table compares Codexis and Cyclo Therapeutics’ net margins, […]

Codexis, Inc. (NASDAQ:CDXS – Get Rating) has earned an average rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average […]

[296 Pages Report] The rapidly increasing prevalence of chronic diseases around the world is expected to fuel the need for novel drugs and better treatment option would further drive the growth of the global market. Due to increasing demand for novel drugs option, there has been rising applications of drug intermedi...

Analysts expect Codexis, Inc. (NASDAQ:CDXS – Get Rating) to report sales of $38.74 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Codexis’ earnings, with estimates ranging from $35.30 million to $42.30 million. Codexis reported sales of $25.45 million in the same quarter last year, which indicates a […]

SEATTLE, May 19, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global synthetic biology market is estimated to be valued at US$...

According to Coherent Market Insights, the global synthetic biology market is estimated to be valued at US$ 13.9 billion in 2022 and is expected to exhibit a

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore,

Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors - read this article along with other careers information, tips and advice on BioSpace